Scientists conducted the first pilot study in humans to observe the impact of the bacterium Akkermansia. Results: the bacterium limits the increase of several risk factors for cardiovascular diseases, moderates the progression of pre-diabetes and reduces cholesterol levels in humans. A major discovery since one in two individuals is overweight and cardiovascular risk factors. Next step? Researchers plan larger-scale tests and the commercialization of the bacteria.
